Table 1.
Summary of studies included in the PPK analysis
| Study code | Phase of study | Cancer indication | Ramucirumab dose (mg kg−1)a | Number of patients with PK samples | Mean samples per patient |
|---|---|---|---|---|---|
| I4T‐MC‐JVBB (RAISE) | 3 | Colorectal | 8 | 431 | 4 |
| I4T‐MC‐JVBA (REVEL) | 3 | Nonsmall cell lung | 10 | 399 | 3 |
| I4T‐IE‐JVBF (REACH) | 3 | Hepatocellular | 8 | 312 | 3 |
| I4T‐IE‐JVBE (RAINBOW) | 3 | Gastric | 8 | 321 | 4 |
| I4T‐IE‐JVBD (REGARD) | 3 | Gastric | 8 | 72 | 2 |
| I4T‐IE‐JVCA | 2 | Solid tumours | 8 | 36 | 12 |
| I4T‐IE‐JVCC | 2 | Solid tumours | 10 | 17 | 13 |
| I4T‐IE‐JVBJ | 2 | Nonsmall cell lung | 10 | 32 | 7 |
| I4T‐IE‐JVBW | 1b | Gastric | 8 | 6 | 28 |
| I4T‐IE‐JVBX | 1b | Metastatic breast | 10 | 7 | 27 |
| I4T‐IE‐JVBY | 1b | Colorectal | 8 | 6 | 18 |
a
Administered as an intravenous infusion over approximately 60 minutes, at either 8 mg kg−1 every 2 weeks (Q2W) on a 14‐ or 28‐day cycle or 10 mg kg−1 every 3 weeks (Q3W) on a 21‐day cycle.